Japanese Banks Stock News

TSE:9104
TSE:9104Shipping

Elliott Pushes Mitsui O.S.K. Lines To Reassess Value And Capital Use

Elliott Investment Management publicly urged Mitsui O.S.K. Lines (TSE:9104) to pursue a more ambitious strategy. The activist investor is calling for an enhanced medium term plan and a premium market valuation for the company. Elliott signaled its intention to engage with management to seek changes it believes could increase shareholder value. Mitsui O.S.K. Lines is a major Japanese shipping group with exposure to global trade, energy transport, and logistics services. The sector is...
TSE:5019
TSE:5019Oil and Gas

Is It Too Late To Consider Idemitsu Kosan (TSE:5019) After Its Strong Recent Share Price Run?

Wondering whether Idemitsu KosanLtd at ¥1,488.5 is priced attractively or already reflects much of its story? This article walks through the key valuation angles to help you frame that question. The stock has moved 5.1% over the last 30 days and 26.2% year to date, with a 33.2% return over the past year and very large gains over 3 and 5 years. This naturally raises questions about how the current price compares with its fundamentals and risks. Recent coverage of Idemitsu KosanLtd has focused...
TSE:8473
TSE:8473Capital Markets

Does SBI Holdings (TSE:8473) Higher Dividend Signal Evolving Capital Priorities Or Strategy Shift?

Earlier in March 2026, SBI Holdings’ board approved a revision to its year-end dividend forecast to ¥75 per share, reflecting profit levels in its Financial Services Business, and later met again to consider converting a second-tier subsidiary into a direct subsidiary. The higher dividend forecast, equivalent to ¥150 per share before the stock split and ¥10 above the prior year, highlights management’s willingness to return more cash to shareholders while potentially reshaping the group...
TSE:4507
TSE:4507Pharmaceuticals

Shionogi (TSE:4507) Valuation Check After XOCOVA Post Exposure COVID 19 Approval

Shionogi (TSE:4507) is back in focus after Japan approved an expanded indication for its anti SARS-CoV-2 drug XOCOVA for post-exposure prophylaxis of COVID-19, grounded in positive global Phase 3 data. See our latest analysis for Shionogi. The XOCOVA approval has arrived alongside other pipeline updates, and the share price has reflected this with a 19.97% 90 day share price return and a 51.24% 1 year total shareholder return, suggesting momentum has been building over time. If you want to...
TSE:7733
TSE:7733Medical Equipment

Olympus (TSE:7733) Valuation Check After VISERA ELITE III Surgical Imaging Launch

Olympus (TSE:7733) is back in the spotlight after the U.S. launch of its VISERA ELITE III surgical imaging platform, a multi-specialty system that combines True 4K, 3D imaging, and software-driven workflow tools. See our latest analysis for Olympus. Despite the VISERA ELITE III launch putting Olympus back on investors' radar, the 1-day and 7-day share price returns of 2.25% and 4.45% sit against a weaker backdrop, with a 90-day share price return of a 28.84% decline and a 1-year total...